Executive chairman Paul Hopper authorised the announcement, noting that Radiopharm’s strategy is to develop a differentiated platform of radiopharmaceutical products across peptides, small molecules, and antibodies.
Radiopharm Theranostics accelerates HER2 cancer trial after positive safety review
October 1, 2025 Australian Biotech
Latest Video
New Stories
-
If the UK has blinked on pharmaceutical pricing, Australia might have to pay attention
October 2, 2025 - - Latest News -
Rising influenza deaths spark call for nurse-led vaccination clinics
October 1, 2025 - - Latest News -
Radiopharm Theranostics accelerates HER2 cancer trial after positive safety review
October 1, 2025 - - Australian Biotech -
dorsaVi achieves breakthrough in robotic reflex intelligence
October 1, 2025 - - Australian Biotech -
New Zealand resets medical device procurement after years of paralysis
October 1, 2025 - - Latest News -
INOVIQ publishes breakthrough data on next-generation cancer therapy
October 1, 2025 - - Australian Biotech -
Cancer vaccine collaboration lands on the Gold Coast
October 1, 2025 - - Australian Biotech